Long-term outcomes of deep brain stimulation for VPS16-related dystonia: A multi-center international study
Objective: To evaluate long-term effects of DBS in an international cohort of people with VPS16-related dystonia. Background: Variants in VPS16 gene have recently been related…Digital gait and turning impairments (quality but not quantity) during daily life are more severe in retrospective fallers compared to non-fallers with Parkinson’s disease
Objective: To investigate which specific digital gait and turning measures, obtained with body-worn sensors, best differentiate fallers from non-fallers with PD during daily life. Background:…Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study
Objective: To evaluate three-year outcomes from the ND0612 BeyoND study. Background: Investigational ND0612 is in development as a 24-hour continuous, subcutaneous infusion of liquid levodopa/carbidopa…The neuroprotective miRNA family hsa-miR-451 has a distinctive pattern of downregulation in neurodegenerative diseases.
Objective: 1.Identification of microRNAs from whole blood PBMCs of SCA2 patients by using NGS. 2.To check the exclusivity of miRNAs in SCA2, SCA1,SCA3,SCA12,HD,ALS,PD and MSA-C…Informing people with Parkinson’s disease of their gene variant status: PD GENEration, a North American observational and registry study
Objective: To describe genetic testing results of major genes for Parkinson’s disease (PD) in a North American cohort as part of PD GENEration Background: Although…Motor complications in Parkinson’s disease
Objective: To determine the presence, severity, functional impact and predisposing factors of motor complications. Background: Motor complications are well recognized in Parkinson’s disease (PD), but…SAFE-DBS – A monocentric, randomised, blind evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation
Objective: This monocentric, randomised, blind study is designed to evaluate the effect of safinamide on motor and neuropsychiatric symptoms in the 3 month perioperative period…Understanding patient perceptions of advanced Parkinson’s disease (aPD) treatments
Objective: To explore patients’ perceptions of treatment options for aPD and treatment decision considerations. Background: As PD advances, some people with Parkinson’s (PwP) on oral…Early-onset cortico-basal degeneration (CBD) due to a c.2092G>A MAPT mutation
Objective: To describe a patient with early-onset atypical parkinsonism that evolved to a classic CBD without dementia, associated to a c.2092G>A MAPT mutation Background: Although…Electronic Development of the MDS-UPDRS and MDS-NMS: Process and User Feedback
Objective: To describe the processes for development and obtaining user feedback of the electronic versions of the MDS Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and…
- « Previous Page
- 1
- …
- 459
- 460
- 461
- 462
- 463
- …
- 1734
- Next Page »